Format

Send to

Choose Destination
IDrugs. 2003 Feb;6(2):159-63.

Ruboxistaurin (Eli Lilly).

Author information

1
102-711 West 17th Avenue, Vancouver, BC V5Z 1V1, Canada. editor@greyowltutor.com

Abstract

Eli Lilly & Co is developing the protein kinase C (PKC)-b inhibitor ruboxistaurin, the lead compound from a series of 14-membered macrocycles, for the potential treatment of diabetic retinopathy, diabetic peripheral neuropathy and macular edema.

PMID:
12789620
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center